Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma

Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma

<p dir="ltr">This report highlights the risk of latent tuberculosis (TB) reactivation after treatment with Polatuzumab Vedotin (PV), Rituximab, and Bendamustine (PBR protocol) despite appropriate chemoprophylaxis. A 48‐year‐old male with refractory Burkitt's lymphoma (BKL) was t...

Full description

Saved in:
Bibliographic Details
Main Author: Sarah A. Elkourashy (21632903) (author)
Other Authors: Maria Benkhadra (19756941) (author), Laila Shafei (17045772) (author), Sulieman Abujarir (21632906) (author), Rola Ghasoub (16555851) (author)
Published: 2024
Subjects:
Biomedical and clinical sciences
Immunology
Oncology and carcinogenesis
Pharmacology and pharmaceutical sciences
bendamustine
Burkitt's lymphoma
polatuzumab vedotin
reactivation
rituximab
tuberculosis
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items